P c src

Primary antibody for VCAM‐1 (GTX110684; 1:1000) and ICAM‐1 (GTX100450; 1:1000) was acquired from GeneTex International Corporation. The p‐phospholipase Cβ (p‐PLCβ) (2481S; 1:1000), PLCβ (14247S; 1:1000), p‐protein kinase Cα (p‐PKCα) (9375S; 1:1000), cellular Src (c‐Src) (2109S; 1:1000), p‐c‐Src (5473S; 1:1000), c‐Jun (9165S; 1:1000) and p‐c‐Jun (2361S; 1:1000) were acquired from Cell Signaling Technology. PKCα (SC2081240; 1:1000) was acquired from Santa Cruz Biotechnology. β‐actin (SI‐A5441; 1:10,000) and secondary antibody for anti‐rabbit and anti‐mouse were acquired from Merck KGaA. Inhibitors for PLCβ (GF109203X; AB‐144264), PKCα (U73122; U6756), c‐Src (PP2; SI‐P0042) and c‐Jun (curcumin; C7727 and tanshinone IIA; T4952) were acquired from Sigma‐Aldrich. Specific neutralizing antibodies for CX3CL1 (AF365‐SP) and CX3CR1 (AF5825) were acquired from Novus Biologicals. Human recombinant protein CX3CL1 (300–31) was acquired from PeproTech and dissolved according to the manufacturer's manual. All other chemicals and reagents were acquired from Sigma‐Aldrich.

TAM and 18α-GA were provided by Sigma-Aldrich (St. Louis, MO, USA). TGF-β1 was obtained from Pepro Tech (Rocky Hill, NJ, USA). MS-275 was supplied by MedChemExpress (Monmouth Junction, NJ, USA). Antibodies against Cx43 and α-SMA were obtained from Abcam (Cambridge Science Park, Cambridge, England). E-ca, N-ca, p-Akt, Akt, c-Src and p-c-Src antibodies and LY294002 (PI3K inhibitor) were purchased from Cell Signaling Technology (Danvers, MA, USA). β-actin and GAPDH antibodies were purchased from Bioworld Technology, Co, Ltd. (Nanjing, China). Dasatinib was from Aladdin Bio-Chem Technology Co.LTD (Shanghai, China). IGF-1 was from PeproTech, Inc. (Rocky Hill, USA). Other reagents were all provided from Sigma-Aldrich unless otherwise noted.